Skip to main content
Clinical Trials/KCT0003698
KCT0003698
Not yet recruiting
未知

Safety, effectiveness, and economic evaluation of adjuvant moxibustion therapy for aromataseinhibitor (AI)-induced arthralgia of postmenopausal breast cancer stage ?–? patients: a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial

Kyung Hee University0 sites46 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Kyung Hee University
Enrollment
46
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional Study
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Female, aged 45 to 65, who have missed menstrual periods in a row for at least 1 year (amenorrhea) or is showing 45mIU/mL or higher of serum follicle\-stimulating hormone
  • 2\) Estrogen receptor positive breast cancer patients of stage I to III, who have completed surgical procedures, chemotherapy, and/or radiation therapy and planned no more active treatments
  • 3\) Patients who have been taking the 3rd generation aromatase inhibitors (anastrozole, letrozole, etc.) for 3 months or more and plan to continue the oral administration while participating in this study
  • 4\) Patients who are complaining arthralgia in one or more joints, newly developed after the administration of the aromatase inhibitors
  • 5\) 4 points or higher of the maximum pain level, assessed with Brief Pain Inventory\-Short Form at screening assessment
  • 6\) Volunteers who signed the informed consent forms

Exclusion Criteria

  • 1\) Primary/metastatic residual cancer or recurrent cancer
  • 2\) History of fracture or surgery in the joints where the pain exists within 3 months
  • 3\) History of moxibustion therapy in the joints with aromatase inhibitor\-induced arthralgia within 3 months
  • 4\) Present administration of steroid/narcotic analgesics
  • 5\) History of allergy to moxibustion or keloid, presence of skin diseases on body parts for moxibustion therapy
  • 6\) Refusal to therapy due to moxibustion fear
  • 7\) Participation in another clinical study within 1 month
  • 8\) Any other inappropriate reasons to participate in the study, judged by the investigators

Outcomes

Primary Outcomes

Not specified

Similar Trials